Attenuated GLP-1 secretion in obesity: Cause or consequence?

Gut

Volumn 38, Issue 6, 1996, Pages 916-919

  Ranganath, L R ^a   Beety, J M ^a   Morgan, L M ^a   Wright, J W ^a   Howland, R ^a   Marks, V ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

carbohydrate meal; fat meal; GLP 1; obesity

Indexed keywords

ADULT; ANTIGEN SPECIFICITY; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; FAT INTAKE; FEMALE; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HORMONE RESPONSE; HUMAN; INSULIN RESISTANCE; OBESITY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030055478     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.6.916     Document Type: Article

References (19)

1. Inoue S. Metabolic effects of autonomic nervous activity in development of obesity (ventromedial obesity). In: Oomura Y, et al, eds. Progress in obesity research. London: John Libbey, 1990: 95-101.
2. Bailey CJ, Flatt PR. Animal models of diabetes. In: Nattrass M, ed. Recent advances in diabetes. Edinburgh: Churchill Livingstone, 1986: 71-89.
3. Zunz E, LeBarre J. Contributions a l'etude des variations physiologiques de la secretion interne du pancreas: relations entre les secretions externe et intern du pancreas. Arch Int Physiol Biochem 1929; 31: 20-44.
4. McIntyre N, Holdsworth DC, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964; ii: 20-1.
5. Morgan LM. Insulin secretion and the enteroinsular axis. In: Flatt P, ed. Nutrient regulation of insulin secretion. London: Portland Press, 1992: 1-22.
6. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-71.
7. Bell GI, Santerre RF, Mullenbach GI. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 712-8.
8. Holst JJ, Orskov G, Nielsen OV, Schwartz. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-74.
9. Kreyman B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 (7-36): A physiological incretin in man. Lancet 1987; ii: 1300-3.
10. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic effects of glicagon-like peptide-1 7-36 amide and glucagon-like peptide-1 7-36 in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-61.
11. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-22.
12. Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, et al. Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients. Diabet Med 1993; 10: 44-9.
13. Beety JM. The role of gastrointestinal hormones in the deposition and mobilisation of lipids in adipose tissue. PhD Thesis. Guildford: University of Surrey, 1994.
14. Hampton SM. C peptide of proinsulin: its diagnostic use and possible physiological role. PhD Thesis. Guildford: University of Surrey, 1984.
15. Morgan LM, Morris BA, Marks V. Radioimmunoassay of gastric inhibitory polypeptide. Ann Clin Biochem 1978; 15: 172-7.
16. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like polypeptide-1 (7-36) amide and glucose dependent insulinotropic polypeptide in response to nutrient ingestion in man: acute postprandial and 24 hr secretion pattern. J Endocrinol 1993; 138: 159-66.
17. Ensinck JW, D'Alessio DA, The enteroinsular axis revisited: a novel role for an incretin. N Engl J Med 1992; 326: 1352-3.
18. Randle PJ, Garland RB, Hales CN, Newsholme EA. The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitis. Lancet 1963; i: 785-9.
19. Bjorntorp P, Bergman H, Vamauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand 1969; 185: 351-6.